{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:57:15Z","timestamp":1781704635092,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["HT9425-23-1-0191"],"award-info":[{"award-number":["HT9425-23-1-0191"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["P30CA072720-5924"],"award-info":[{"award-number":["P30CA072720-5924"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["NCI-CCSG P30CA072720-6852"],"award-info":[{"award-number":["NCI-CCSG P30CA072720-6852"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA251438"],"award-info":[{"award-number":["R01CA251438"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jconrel.2025.114584","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:18:06Z","timestamp":1766992686000},"page":"114584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Engineered tumor-tropic mesenchymal stem cells as targeted therapeutic delivery systems for refractory Ovarian cancer"],"prefix":"10.1016","volume":"390","author":[{"given":"Geng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Massumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajar","family":"Owji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Girda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Hatefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114584_bb0005","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ygyno.2005.10.013","article-title":"The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer","volume":"100","author":"Matsumoto","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0010","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/stem.1198","article-title":"Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-alpha-activated endothelial cells via both leukocyte-like and novel mechanisms","volume":"30","author":"Teo","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.jconrel.2025.114584_bb0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/0008-5472.CAN-15-1563","article-title":"Peritoneal dissemination requires an Sp1-dependent CXCR4\/CXCL12 signaling Axis and extracellular matrix-directed spheroid formation","volume":"76","author":"Kasagi","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114584_bb0020","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1634\/stemcells.2007-0054","article-title":"The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities","volume":"25","author":"Ponte","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.jconrel.2025.114584_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1741-7015-11-139","article-title":"Tissue-derived mesenchymal stromal cells used as vehicles for anti-tumor therapy exert different in vivo effects on migration capacity and tumor growth","volume":"11","author":"Belmar-Lopez","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.jconrel.2025.114584_bb0030","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/stem.187","article-title":"Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging","volume":"27","author":"Kidd","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.jconrel.2025.114584_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19071930","article-title":"Recent Progress in gene therapy for ovarian Cancer","volume":"19","author":"Ayen","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.114584_bb0040","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1089\/scd.2016.0064","article-title":"Metastatic ovarian Cancer can be efficiently treated by genetically modified mesenchymal stromal cells","volume":"25","author":"Toro","year":"2016","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.jconrel.2025.114584_bb0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jconrel.2019.09.006","article-title":"Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis","volume":"311-312","author":"Malekshah","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114584_bb0050","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1517\/17425255.4.9.1153","article-title":"Modifications of human carboxylesterase for improved prodrug activation","volume":"4","author":"Hatfield","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/0929867033368619","article-title":"Lessons learned from the irinotecan metabolic pathway","volume":"10","author":"Ma","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114584_bb0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2015.01.003","article-title":"Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme\/prodrug systems","volume":"200","author":"Nouri","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114584_bb0065","first-page":"2083","article-title":"Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells","volume":"29","author":"Torigoe","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2025.114584_bb0070","first-page":"945","article-title":"Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells","volume":"19","author":"Takeda","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2025.114584_bb0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12032-023-01975-1","article-title":"Stem cell-assisted enzyme\/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands","volume":"40","author":"Li","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2015.05.009","article-title":"Progress and problems with the use of suicide genes for targeted cancer therapy","volume":"99","author":"Karjoo","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114584_bb0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40495-016-0073-y","article-title":"Enzyme\/prodrug systems for cancer gene therapy","volume":"2","author":"Malekshah","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.jconrel.2025.114584_bb0090","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.034199","article-title":"Modeling the effect of ascites-induced compression on ovarian cancer multicellular aggregates","volume":"11","author":"Klymenko","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.jconrel.2025.114584_bb0095","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.canlet.2016.11.034","article-title":"Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer","volume":"388","author":"Auer","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2025.114584_bb0100","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.biocel.2016.07.017","article-title":"Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines","volume":"78","author":"Januchowski","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12885-016-2071-1","article-title":"Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines","volume":"16","author":"Jandu","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2025.114584_bb0110","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1002\/cam4.1631","article-title":"A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer","volume":"7","author":"Sarkar","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.jconrel.2025.114584_bb0115","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.2174\/1389450117666160502151707","article-title":"Strategies targeting DNA topoisomerase I in cancer chemotherapy: camptothecins, nanocarriers for camptothecins, organic non-camptothecin compounds and metal complexes","volume":"17","author":"Gokduman","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.jconrel.2025.114584_bb0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/gt.2012.12","article-title":"Neural stem cell-mediated CE\/CPT-11 enzyme\/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma","volume":"20","author":"Gutova","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2025.114584_bb0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00280-010-1272-6","article-title":"Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding","volume":"67","author":"Choi","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/GCO.0000000000000432","article-title":"The target invites a foe: antibody-drug conjugates in gynecologic oncology","volume":"30","author":"Campos","year":"2018","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0135","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fonc.2020.00118","article-title":"Preclinical activity of Sacituzumab Govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer","volume":"10","author":"Perrone","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1749-6632.2000.tb07046.x","article-title":"In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs","volume":"922","author":"Bernacki","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.114584_bb0145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/gyno.2000.5793","article-title":"Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up","volume":"77","author":"Morgan","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ygyno.2004.06.029","article-title":"Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study","volume":"95","author":"Pectasides","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0155","first-page":"2933","article-title":"G. Japan gynecologic oncology, Phase I study of irinotecan combined with mitomycin-C and 5-fluorouracil for gynecological malignancies: the JGOG study","volume":"28","author":"Kokawa","year":"2008","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2025.114584_bb0160","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2003.02.091","article-title":"Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer","volume":"21","author":"Bodurka","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0165","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00280-017-3468-5","article-title":"Combination chemotherapy with irinotecan and gemcitabine for taxane\/platinum-resistant\/refractory ovarian and primary peritoneal cancer: a multicenter phase I\/II trial (GOGO-Ov 6)","volume":"80","author":"Yoshino","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0170","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.3892\/ol.2016.4937","article-title":"ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan","volume":"12","author":"Tuy","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jconrel.2025.114584_bb0175","article-title":"Molecular mechanisms of cisplatin resistance in ovarian cancer","volume":"11","author":"Jiang","year":"2024","journal-title":"Genes. Dis."},{"key":"10.1016\/j.jconrel.2025.114584_bb0180","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Gynecologic oncology, intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114584_bb0190","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5306\/wjco.v10.i5.201","article-title":"Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer","volume":"10","author":"Meghal","year":"2019","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2005.12.006","article-title":"Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma","volume":"100","author":"Trimble","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0205","article-title":"Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.114584_bb0210","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.exphem.2004.02.004","article-title":"Mesenchymal stem cells: paradoxes of passaging","volume":"32","author":"Javazon","year":"2004","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11373-004-8183-7","article-title":"T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression","volume":"12","author":"Klyushnenkova","year":"2005","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2025.114584_bb0220","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nbt.2816","article-title":"Mesenchymal stem cells: immune evasive, not immune privileged","volume":"32","author":"Ankrum","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-3083.2003.01176.x","article-title":"Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex","volume":"57","author":"Le Blanc","year":"2003","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jconrel.2025.114584_bb0230","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1158\/1078-0432.CCR-16-1518","article-title":"Neural stem cell-based anticancer gene therapy: a first-in-human study in recurrent high-grade glioma patients","volume":"23","author":"Portnow","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114584_bb0235","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41551-023-01133-y","article-title":"Immune-privileged tissues formed from immunologically cloaked mouse embryonic stem cells survive long term in allogeneic hosts","volume":"8","author":"Harding","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2025.114584_bb0240","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat. Biotechnol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925011988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925011988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:23:30Z","timestamp":1781702610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925011988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":48,"alternative-id":["S0168365925011988"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114584","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered tumor-tropic mesenchymal stem cells as targeted therapeutic delivery systems for refractory Ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114584"}}